Zimbabwe has rejected a significant American health deal worth 367 million US dollars (272 million pounds) spanning five years over the United States' request for confidential information.
This move was revealed following a official document from December was disclosed, revealing that President Emmerson Mnangagwa felt the agreement was "unbalanced".
A government spokesman has since stated that the US was demanding access to biological samples for research and profit while was not willing to guarantee the resulting advantages from any future treatments.
"We will now turn to the challenging and unfortunate process of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated more than $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more talks to secure a agreement acceptable to all parties so the country's vital HIV treatment initiative can be sustained.
Wider Implications
This development follows a comparable situation in Kenya, where a court suspended a similar deal with the US following legal challenges were raised about the safety of Kenyans' health data.
After resuming office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was pursuing direct bilateral agreements to boost openness and responsibility.
According to reports, Sixteen African countries have to date agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered significant advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment through US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to provide its genetic material and health information for a long time, without any corresponding guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," Mangwana explained.
"In essence, our nation would provide the basic resources for scientific discovery without any assurance that the end products would be available to our population if a future disease outbreak arise."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of bilateral health agreements were upending structures already established via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to manage future pandemics.
"This mechanism is intended to ensure that when a country contributes its data, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
These objections over the US deal "are not meant as opposition to America," he added.
"We encourage further dialogue with our US partners on how subsequent collaboration might be designed in a way that honours the sovereignty and interests of each country."
Health Experts Reaction
Medical experts stated it understood the official position, but recommended that negotiations need to persist given that much of the nation's Aids initiatives relied on international support.
"Where specific concerns exist, such as those relating to information security or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," it commented.
The halted deal underscores the continuing tensions between accepting vital foreign assistance and protecting a country's data in an ever more data-driven world.